In children treated with radioactive iodine for Graves' disease, no increased risk of cancer or reduced quality of life was found in the studies reviewed, suggesting these risks are very low or undetectable with current methods.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of long-term cohort studies with individual patient data would definitively assess whether RAI increases cancer risk over 20–30 years in pediatric Graves' disease.
A systematic review and meta-analysis of all prospective cohort studies with individual-level data on children aged <18 treated with RAI for Graves' disease, with minimum 20-year follow-up, standardized cancer ascertainment via national registries, and adjustment for age at treatment, dose, and genetic risk factors.
An RCT with long-term follow-up would determine whether RAI causally affects cancer risk or quality of life compared to surgery, but ethical constraints limit feasibility.
A multicenter RCT enrolling 1,000 children aged 8–18 with Graves' disease randomized to RAI or thyroidectomy, with primary outcomes: cancer incidence (all sites) and validated quality of life scores (PedsQL) at 10, 20, and 30 years, with mandatory reporting to national cancer registries.
A prospective cohort study with long-term follow-up could detect trends in cancer incidence or quality of life decline after RAI, though power remains limited for rare outcomes.
A prospective multicenter cohort study following 5,000 children aged 8–18 treated with RAI for Graves' disease, with annual thyroid function testing, biennial cancer screening, and quality of life assessments via PedsQL, linked to national cancer registries for 30 years.
A case-control study could compare cancer incidence in children treated with RAI versus those treated with surgery or medication, but is prone to recall and selection bias.
A matched case-control study comparing 500 children diagnosed with thyroid, breast, or leukemia cancer before age 25 with 2,000 matched controls, assessing prior RAI exposure for Graves' disease, dose, and age at treatment.
A cross-sectional study could estimate current prevalence of cancer or low quality of life in RAI-treated children, but cannot determine if RAI caused these outcomes.
A national cross-sectional survey of 10,000 adults aged 20–40 who received RAI for Graves' disease in childhood, assessing current cancer history and quality of life (SF-36), stratified by age at RAI and dose.